{
    "clinical_study": {
        "@rank": "156474", 
        "arm_group": [
            {
                "arm_group_label": "EVP-6124, low dose", 
                "arm_group_type": "Experimental", 
                "description": "low dose, Tablet, Once Daily, Day 1 through Day 182"
            }, 
            {
                "arm_group_label": "EVP-6124, high dose", 
                "arm_group_type": "Experimental", 
                "description": "high dose, Tablet, Once Daily, Day 1 through Day 182"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled\n      studies, EVP-6124-024 and EVP-6124-025.  In this extension study, subjects who complete\n      study EVP-6124-024 or EVP-6124-025 and fulfill all entry criteria will be randomized to\n      receive EVP-6124 for an additional 26 weeks."
        }, 
        "brief_title": "Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025", 
        "condition": [
            "Alzheimer's Disease", 
            "Dementia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Dementia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects of any race, aged \u226555 and \u226485 years at time of entry into\n             study EVP-6124-024 or EVP-6124-025\n\n          -  Informed consent form (ICF) for this extension study signed by the subject or legally\n             acceptable representative and an ICF signed by the support person/caregiver before\n             initiation of any study-specific procedures\n\n          -  Successful completion (Day 182) of study EVP-6124-024 or EVP-6124-025\n\n          -  No clinically significant change in the judgment of the investigator in the subject's\n             medical status during study EVP-6124-024 or EVP-6124-025\n\n          -  In the judgment of the investigator, extension treatment is in the best interest of\n             the subject\n\n          -  Fertile, sexually active subjects (men and women) must use an effective method of\n             contraception during the study.  Female subjects and the female partner of male\n             subjects must be surgically sterile (hysterectomy or bilateral tubal ligation),\n             postmenopausal for at least 1-year, or willing to practice adequate methods of\n             contraception if of childbearing potential (defined as consistent use of combined\n             effective methods of contraception [including at least 1 barrier method])\n\n          -  Reliable and capable support person/caregiver, who if not living in the same\n             household, interacts with the subject approximately 4 times per week and will be\n             available to attend clinic visits in person when possible\n\n        Exclusion Criteria:\n\n          -  Significant risk of suicidal or violent behavior in the judgment of the investigator\n\n          -  Adverse events from the previous study (EVP-6124-024 or EVP-6124-025) that have not\n             resolved, are moderate or severe, judged to be possibly related or related to study\n             drug, and considered by the investigator to be a contraindication to extension study\n             participation\n\n          -  Any condition that would make the subject in the judgment of the investigator\n             unsuitable for the study\n\n          -  Female subjects who are pregnant, nursing, or planning to become pregnant during the\n             extension study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004392", 
            "org_study_id": "EVP-6124-026", 
            "secondary_id": "2013-002654-75"
        }, 
        "intervention": {
            "arm_group_label": [
                "EVP-6124, low dose", 
                "EVP-6124, high dose"
            ], 
            "intervention_name": "EVP-6124", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cholinesterase Inhibitors"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Alzheimer's disease", 
            "Cognition", 
            "Alpha-7 nAChR"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Encino", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooksville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creve Coeur", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication", 
        "overall_contact": {
            "email": "sguillaume@forumpharma.com", 
            "last_name": "Sophie Guillaume", 
            "phone": "617-374-5705"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Ministry of Health", 
                "Australia: National Health and Medical Research Council", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: The Italian Medicines Agency", 
                "Japan: Ministry of Health, Labor and Welfare", 
                "Mexico: Ministry of Health", 
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Portugal: National Authority of Medicines and Health Products", 
                "South Africa: Medicines Control Council", 
                "South Korea: Ministry of Food and Drug Safety", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Criteria for evaluation include: adverse events, clinical laboratory tests, vital signs, body weight, 12-lead ECG, physical examination, concomitant medications, C-SSRS, and GDS.", 
            "measure": "Safety of 2 fixed doses of EVP-6124 for up to 52 weeks in subjects with Alzheimer's disease who complete study EVP-6124-024 or EVP-6124-025", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to Day 182 or Early Termination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004392"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in cognition using the Mini-Mental State Examination (MMSE)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 182 or Early Termination"
            }, 
            {
                "measure": "Change from Baseline in psychiatric and behavioral symptoms using the Neuropsychiatric Inventory (NPI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 182 or Early Termination"
            }, 
            {
                "measure": "Change from Baseline in quality of life using the EuroQol-5D (EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 182 or Early Termination"
            }, 
            {
                "measure": "Pharmacoeconomic outcomes using the Resource Utilization in Dementia (RUD-Lite 3.3)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 182 or Early Termination"
            }, 
            {
                "measure": "Caregiver perceived burden using the Zarit Burden Interview (ZBI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 182 or Early Termination"
            }
        ], 
        "source": "FORUM Pharmaceuticals Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "FORUM Pharmaceuticals Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}